Merck may be near NuvaRing settlement

Share this article:

Merck may be poised to settle lawsuits over its NuvaRing contraceptive for $100 million—a bargain, Bloomberg notes, compared to drugmakers such as Bayer, which has paid more than $1.6 billion over claims surrounding its birth control pills Yaz and Yazmin.

Women and families have sued the company, saying the drugmaker knew the contraceptive triggered a higher risk of heart attack and blood clots than competing products. Merck told Bloomberg that the proposed settlement is not an admission of wrongdoing and the company stands behind the contraceptive.

Ninety-five percent of the 3,800 plaintiffs need to agree to the settlement or Merck can walk away.

Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Business Briefs

The Women's Health landscape is ripe with opportunity for pharma marketers. This seven-page eBook offers product managers a guide to capitalizing on the trends, growth areas and unmet needs. Includes alternative channels to engage OB/GYNs and oncologists, and plenty of tips. Click here to access it.

Email Newsletters